SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Mereo BioPharma Group plc American Depositary Shares and Sets a Lead Plaintiff Deadline of April 6, 2026

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit, Megan Dodge v. Mereo BioPharma Group plc, was initiated in the United States District Court for the Southern District of New York for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - Investors are encouraged to participate in the lawsuit before the April 6, 2026 deadline to potentially recover losses [5]. Group 2: Study Results - Mereo announced on December 29, 2025, that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet the primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [3]. - Despite improvements in bone mineral density, the studies did not yield the expected results, leading to significant investor concerns [2][3]. Group 3: Market Reaction - Following the announcement of the study results, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [4].